参考文献/References:
[1] ZHU J,CHEN Z,LALLEMAND-BREITENBACH V,et al.How acute promyelocytic leukaemia revived arsenic[J].Nat Rev Cancer,2002,2(9):705-713.
[2] LIU J X,ZHOU G B,CHEN S J,et al.Arsenic compounds:Revived ancient remedies in the fight against human malignancies[J].Curr Opin Chem Biol,2012,16(1-2):92-98.
[3] SHEN Z X,CHEN G Q,NI J H,et al.Use of arsenic trioxide(As2O3)in the treatment of acute promyelocytic leukemia(APL):Clinical efficacy and pharmacokinetics in relapsed patients[J].Blood,1997,89(9):3354-3360.
[4] SOIGNET S L,FRANKEL S R,DOUER D,et al.United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia[J].J Clin Oncol,2001,19(18):3852-3860.
[5] ABAZA Y,KANTARJIAN H,GARCIA-MANERO G,et al.Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid,arsenic trioxide,and gemtuzumab[J].Blood,2017,129(10):1275-1283.
[6] MATHEWS V,GEORGE B,CHENDAMARAI E,et al.Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia:Long-term follow-up data[J].J Clin Oncol,2010,28(24):3866-3871.
[7] ILAND H J,BRADSTOCK K,SUPPLE S G,et al.All-trans-retinoic acid,idarubicin,and Ⅳ arsenic trioxide as initial therapy in acute promyelocytic leukemia(APML4)[J].Blood,2012,120(8):1570-1752.
[8] ZHENG H,JIANG H,HU S,et al.Arsenic combined with all-trans retinoic acid for pediatric acute promyelocytic leukemia:Report from the CCLG-APL2016 protocol study[J].J Clin Oncol,2021,39(28):3161-3170.
[9] MUNSHI N C,TRICOT G,DESIKAN R,et al.Clinical activity of arsenic trioxide for the treatment of multiple myeloma[J].Leukemia,2002,16(9):1835-1837.
[10] SCHILLER G J,SLACK J,HAINSWORTH J D,et al.Phase Ⅱ multicenter study of arsenic trioxide in patients with myelodysplastic syndromes[J].J Clin Oncol,2006,24(16):2456-2464.
[11] BURNETT A K,HILLS R K,HUNTER A,et al.The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome[J].Leukemia,2011,25(7):1122-1127.
[12] WANG H,LIU Y,WANG X,et al.Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma[J].Cancer,2015,121(17):2917-2925.
[13] WANG L,LIANG W,PENG N,et al.The synergistic antitumor effect of arsenic trioxide combined with cytotoxic T cells in pulmonary metastasis model of colon cancer[J].Oncotarget,2017,8(65):109609-109618.
[14] 陈正浤,雷光焰,韩乐,等.三氧化二砷抑制人肺癌细胞NCI-H460增殖并促进其凋亡实验研究[J].陕西医学杂志,2020,49(10):1219-1222,1227.
[15] ZHU J,NASR R,PÉRÈS L,et al.RXR is an essential component of the oncogenic PML/RARA complex in vivo[J].Cancer Cell,2007,12(1):23-35.
[16] LALLEMAND-BREITENBACH V,DETHÉH.PML nuclear bodies:From architecture to function[J].Curr Opin Cell Biol,2018,52:154-161.
[17] LALLEMAND-BREITENBACH V,DETHÉ H.PML nuclear bodies[J].Cold Spring Harb Perspect Biol,2010,2(5):a000661.
[18] DETHÉ H,CHEN Z.Acute promyelocytic leukaemia:Novel insights into the mechanisms of cure[J].Nat Rev Cancer,2010,10(11):775-783.
[19] ZEHIR A,BENAYED R,SHAH R H,et al.Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients[J].Nat Med,2017,23(6):703-713.
[20] CHO Y,GORINA S,JEFFREY P D,et al.Crystal structure of a p53 tumor suppressor-DNA complex:understanding tumorigenic mutations[J].Science,1994,265(5170):346-355.
[21] YU X,VAZQUEZ A,LEVINE A J,et al.Allele-specific p53 mutant reactivation[J].Cancer Cell,2012,21(5):614-625.
[22] JOERGER A C,ANG H C,FERSHT A R.Structural basis for understanding oncogenic p53 mutations and designing rescue drugs[J].Proc Natl Acad Sci USA,2006,103(41):15056-15061.
[23] CHEN S,WU J L,LIANG Y,et al.Arsenic trioxide rescues structural p53 mutations through a cryptic allosteric site[J].Cancer Cell,2021,39(2):225-239.
[24] SONG H,WU J,TANG Y,et al.Diverse rescue potencies of p53 mutations to ATO are predetermined by intrinsic mutational properties[J].Sci Transl Med,2023,15(690):eabn9155.
[25] LU Z,HUNTER T.Prolyl isomerase Pin1 in cancer[J].Cell Res,2014,24(9):1033-1049.
[26] SUIZU F,RYO A,WULF G,et al.Pin1 regulates centrosome duplication,and its overexpression induces centrosome amplification,chromosome instability,and oncogenesis[J].Mol Cell Biol,2006,26(4):1463-1479.
[27] SUN H L,CUI R,ZHOU J,et al.ERK activation globally downregulates miRNAs through phosphorylating exportin-5[J].Cancer Cell,2016,30(5):723-736.
[28] LIOU Y C,SUN A,RYO A,et al.Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration[J].Nature,2003,424(6948):556-561.
[29] KOIKAWA K,KIBE S,SUIZU F,et al.Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy[J].Cell,2021,184(18):4753-4771.
[30] CHEN J,JIN Z,ZHANG S,et al.Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis[J].Cell Mol Immunol,2023,20(1):51-64.
[31] MEDDA N,DE S K,MAITI S.Different mechanisms of arsenic related signaling in cellular proliferation,apoptosis and neo-plastic transformation[J].Ecotoxicol Environ Saf,2021,208:111752.
相似文献/References:
[1]文 栋,王西宾△.99Tcm-MDP全身骨扫描及局部单光子发射计算机断层成像在骨转移性肿瘤诊断中的临床应用*[J].陕西医学杂志,2020,49(7):808.[doi:DOI:10.3969/j.issn.10007377.2020.07.010]
WEN Dong,WANG Xibin..Diagnostic value of 99Tcm-MDP whole body bone scan and local SPECT in bone metastatic tumors[J].,2020,49(5):808.[doi:DOI:10.3969/j.issn.10007377.2020.07.010]
[2]樊 盼,陆建荣,姚俊涛△.颗粒蛋白前体在肿瘤发生和发展中的作用研究进展[J].陕西医学杂志,2020,49(7):910.[doi:DOI:10.3969/j.issn.10007377.2020.07.039]
FAN Pan,LU Jianrong,YAO Juntao..Research progress on the role of progranulin in tumors[J].,2020,49(5):910.[doi:DOI:10.3969/j.issn.10007377.2020.07.039]
[3]陈正浤,雷光焰△,韩 乐,等.三氧化二砷抑制人肺癌细胞NCI-H460增殖并促进其凋亡实验研究*[J].陕西医学杂志,2020,49(10):1219.[doi:DOI:10.3969/j.issn.1000-7377.2020.10.005]
[4]杨 旭,张致英,康龙丽,等.环状RNA与代谢性疾病研究进展[J].陕西医学杂志,2021,50(1):126.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.033]
YANG Xu,ZHANG Zhiying,KANG Longli,et al.Advances in circular RNA and metabolic diseases[J].,2021,50(5):126.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.033]
[5]陈正浤,李媛媛,雷光焰,等.Ⅰ型分裂蛋白转导素样增强子在肿瘤中的作用研究进展[J].陕西医学杂志,2021,50(4):511.[doi:DOI:10.3969/j.issn.1000-7377.2021.04.034]
[6]王 琛,齐广莹.Borealin在肿瘤中的作用及其分子机制研究进展[J].陕西医学杂志,2021,50(8):1038.[doi:DOI:10.3969/j.issn.1000-7377.2021.08.034]
[7]黄 静,陈佳茹,喻 莹,等.抑癌基因BLU在肿瘤中的作用及分子机制研究进展[J].陕西医学杂志,2021,50(11):1462.[doi:DOI:10.3969/j.issn.1000-7377.2021.11.035]
HUANG Jing,CHEN Jiaru,YU Ying,et al.Role and molecular mechanism of tumor suppressor gene BLU in tumors[J].,2021,50(5):1462.[doi:DOI:10.3969/j.issn.1000-7377.2021.11.035]
[8]陈 丹,王文静,王庆雅,等.生物发光成像技术在肿瘤细胞活体可视化研究中的应用研究进展[J].陕西医学杂志,2022,51(1):111.[doi:DOI:10.3969/j.issn.1000-7377.2022.01.028]
CHEN Dan,WANG Wenjing,WANG Qingya,et al.Application of bioluminescence imaging technology in visualization of cancer cells in vivo[J].,2022,51(5):111.[doi:DOI:10.3969/j.issn.1000-7377.2022.01.028]
[9]王 剑,魏媛媛,朱利双,等.长链非编码RNA RAB11B-AS1在胶质瘤中的表达及预后价值研究[J].陕西医学杂志,2023,52(4):399.[doi:DOI:10.3969/j.issn.1000-7377.2023.04.008]
WANG Jian,WEI Yuanyuan,ZHU Lishuang,et al.Expression and prognostic value of lncRNA RAB11B-AS1 in glioma[J].,2023,52(5):399.[doi:DOI:10.3969/j.issn.1000-7377.2023.04.008]
[10]黄丽银,斯 韬,梁 婷,等.丙酮酸脱氢酶激酶4在肝细胞癌中的作用研究进展[J].陕西医学杂志,2023,52(7):934.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.036]
HUANG Liyin,SI Tao,LIANG Ting,et al.Research progress on role of pyruvate dehydrogenase kinase 4 in hepatocellular carcinoma[J].,2023,52(5):934.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.036]